Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
At least some readers of this news-blog may be interested in two items posted earlier today on the Medscape Oncology web site.
Filed under: Management, Treatment | Tagged: active surveillance, minimally invasigve, MIRP, prostatectomy, RALP, robot-assisted | 5 Comments »
According to information on the MSN Money web site, Adamis Pharmaceuticals has received approval from the U.S. Food & Drug Administration of its Investigational New Drug (IND) application and been give approval to initiate a Phase I/IIa clinical trial of APC-100 for the treatment of men with castration-resistant prostate cancer.
Filed under: Drugs in development | Tagged: APC-100 | Leave a Comment »
As long ago as December 2008 we first referred to the possibility that the xenotropic murine leukemia virus-related virus (XMRV) might have some association to risk for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: risk, XMRV | 2 Comments »
A new analysis of data from a large, consecutive series of Swedish patients suggests a very strong correlation between age at time of radical prostatectomy and risk for significant, long-term urinary leakage.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: age, education, incontinence, radical prostatectomy, risk | Leave a Comment »
An article by Crawford and Arangua on page 3 of the June issue of AUA News provides a series of “take home messages” for attendees of the annual meeting of the American Urological Association in Washington, DC, last month.
Filed under: Management, Treatment | Tagged: annual meeting, AUA, localized | 4 Comments »
We are coming to the conclusion that there is a deep divide between how some surgeons think about post-surgical incontinence following radical prostatectomy for their prostate cancer and how patients may think about such incontinence when defined by exactly the same set of clinical symptoms and quality of life issues.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: continence, incontinence, laparoscopic, prostatectomy, RALP, robot-assisted, surgery | Leave a Comment »
As previously reported a little over a year ago, BioSante Pharmaceuticals is trying to re-initiate the development of the GVAX vaccine product for the treatment of prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: GVAX | Leave a Comment »
A new update was provided at the ASCO meeting today on progress from the Phase II clinical trial of XL184 (cabozantinib) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development | Tagged: cabozantinib, outcome, XL184 | 2 Comments »
Perhaps the most interesting new data from the annual meeting of the American Society of Clinical Oncology yesterday (Sunday) was a negative result from a four-arm, randomized clinical trial.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, Effexor, hot flashes, soy, venlaxafine | 3 Comments »
As we have previously reported, the latest analysis of survival data from the pivotal Phase III trial of abiraterone acetate + predisone has shown a slight improvement in the survival benefit for patients treated with abiraterone (Zytiga™).
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, circulating tumor cell, CTC, survival, Zytiga | Leave a Comment »
For men undergoing the combination of external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT), for treatment of prostate cancer there is a significant risk for gastrointestinal (GI) toxicity over time.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, ADT, androgen deprivation, EBRT, gastrointestinal, IMRT, toxicity | Leave a Comment »
Many patients and advocates will benefit from reading (possibly with both horror and pleasure) the article with the above title by Professor Curtis Nickel in the current issue of the Canadian Urological Association Journal. So may many in the urology community.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: bloodletting, outcome, radical prostatectomy | 1 Comment »
A new study by an Austrian research team has further helped to clarify the potential prognostic significance of perineural invasion as a risk factor in the progression of localized and locally advanced forms of prostate cancer.
Filed under: Diagnosis, Management, Uncategorized | Tagged: perineural invasion, prognosis, risk | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site